1-9 of 9
Lijuan Deng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial

Yuqin Song, Haiyan Yang, Youchao Jia, Lixia Sheng, Lijuan Deng, Xi Chen, Yongjing Tang, Xifang Liu, Sijun Liu, Min Wei, Feng Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 6481.
https://doi.org/10.1182/blood-2024-199342
Published: 2024
Journal Articles

Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Lijuan Deng, Yanyan Liu, Ningjing Lin, Zhihua Yao, Jiuyang Zhang, Wei Meng, Qiying Lu, Wenzhi Tian, Jun Zhu, Yuqin Song
Journal: Blood
Blood (2024) 144 (Supplement 1): 3033.
https://doi.org/10.1182/blood-2024-200539
Published: 2024
Journal Articles

Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Lijuan Deng, Tianheng He, Yongjing Tang, Lan Mi, Changyu Lu, Hanxiao Liu, Shupeng Zhong, Jin Chai, Jun Luo, Liling Zhang, Shujuan Wen, Xiaopei Wang, Jun Zhu, Yuqin Song
Journal: Blood
Blood (2024) 144 (Supplement 1): 1735.
https://doi.org/10.1182/blood-2024-209021
Published: 2024
Journal Articles

Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Lijuan Deng, Tianheng He, Di Mei, Yongjing Tang, Changyu Lu, Xian Zhang, Meixiang Zhang, Feng Chen, Xiaopei Wang, Jun Zhu, Yuqin Song
Journal: Blood
Blood (2022) 140 (Supplement 1): 9459–9460.
https://doi.org/10.1182/blood-2022-164632
Published: 2022
Journal Articles

CD19 CAR T Cell Product Exhibits High Remission Rate in Adult Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Zhitao Ying, MD PhD, Wen Wang, MD, Xiaopei Wang, MD, Wen Zheng, MD, Ningjing Lin, MD PhD, Meifeng Tu, MD PhD, Yan Xie, MD PhD, Lingyan Ping, MD PhD, Chen Zhang, MD PhD, Weiping Liu, MD PhD, Lijuan Deng, MD PhD, Ming Hao, Su Yang, Yan Zhou, BSc, James Li, Yuqin Song, MD PhD, Jun Zhu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5388.
https://doi.org/10.1182/blood-2018-99-114527
Published: 2018
Journal Articles

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Scott F Huntington, MD MPH, Stephen J. Schuster, MD, Wei He, PhD, Tong Shen, PhD, Heather Walker, MPH, CCRP, Laura Leary, Kylie Boyhen, Jennifer Gill, CRNP, Elizabeth T Chatburn, BS, Kaitlin Kennard, RN, BSN, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, David L. Porter, MD, Ellen Napier, NP, Mitchell E. Hughes, PharmD, Tanya Latorre, RN, Kristy Walsh, BS, Colleen Dorsey, BSN, RN, Jakub Svoboda, MD, Victoria Addis, MD, Barry Douglas Anderson, MD PhD, Emily Leblond, Yuqin Song, MD PhD, Jun Zhu, MD PhD, Lijuan Deng, MD PhD, Danielle M. Brander, MD, Wei Ding, MD PhD, Allison C. Rosenthal, DO, Han Tun, MD, Anthony R. Mato, MD MSCE
Journal: Blood
Blood (2018) 132 (Supplement 1): 5384.
https://doi.org/10.1182/blood-2018-99-112944
Published: 2018
Journal Articles

Simultaneous Global Phase I Studies of a Differentiated BTK Inhibitor, Dtrmwxhs-12, in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphomas

Yuqin Song, MD, Stephen J. Schuster, MD, Wei He, PhD, Jun Zhu, BS, Lijuan Deng, MD, Yingli Sun, MD, Ning Ding, MD, Xiaogan Wang, MD, Jennifer Gill, NP, MSN, Elizabeth T Chatburn, BS, Kaitlin Kennard, RN, BSN, Barry Douglas Anderson, MD PhD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, David L Porter, MD, Ellen Napier, NP, Mitchell E. Hughes, PharmD, BCPS, BCOP, Tanya Latorre, BSN, RN, Kristy Walsh, BS, Colleen Dorsey, BSN, Jakub Svoboda, MD, Victoria Addis, MD, Anthony R. Mato, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4056.
https://doi.org/10.1182/blood.V130.Suppl_1.4056.4056
Published: 2017
Journal Articles

The Intracellular TCR Signaling Pathway As a Novel Therapeutic Target in AITL Patients

Yalu Liu, Ning Ding, MD, Xiaogan Wang, MD, Lijuan Deng, MD, Lingyan Ping, Yunfei Shi, Wen Zheng, Ningjing Lin, Xiaopei Wang, Meifeng Tu, Yan Xie, Weiping Liu, Zhitao Ying, Chen Zhang, Zhengying Pan, Xi Wang, Yuqin Song, MD, Jun Zhu, BS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1461.
https://doi.org/10.1182/blood.V130.Suppl_1.1461.1461
Published: 2017
Journal Articles

Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Qi Shen, Zijun Yidan Xu-Monette, PhD, Ganiraju Manyam, Carlo Visco, Alexander Tzankov, MD PhD, Xin Cao, Lijuan Deng, Santiago Montes-Moreno, MD PhD, Karen Dybkær, April Chiu, MD, Attilio Orazi, MD, Youli Zu, MD PhD, Govind Bhagat, MD, Kristy L. Richards, MDPhD, Eric D. Hsi, MD, William Choi, Joannes H.J.M. Van Krieken, PhDMD, Jooryung Huh, Maurilio Ponzoni, MD, Andres J.M. Ferreri, MD PhD, John P. Farnen, MD, Michael B. Møller, MD DMSc, Jane N. Winter, MD, Miguel Angel A. Piris, MD PhD, L. Jeffrey Medeiros, MD, Ken H. Young, MD PhD
Journal: Blood
Blood (2014) 124 (21): 143.
https://doi.org/10.1182/blood.V124.21.143.143
Published: 2014